Biography
Incredibly passionate about both research and clinical practice, Dr Karthik Nath incorporates the latest advancements in haematology to ensure the best outcomes for his patients. Dr Nath’s approach is rooted in empathy, respect, and a deep commitment to improving the quality of life for his patients, and ensuring they receive the highest standard of personalised care in a supportive environment.
Dr Karthik Nath is a clinical haematologist at Icon Cancer Centre in South Brisbane, with a strong background in clinical practice and research aimed at advancing the field of haematology and enhancing patient outcomes. He is also Icon’s Deputy Director of Cellular Therapy. Dr Nath also provides weekly consultations services at Brisbane South Private Hospital, Springwood Health Hub in Springwood and monthly consultation services at The Friendlies Medical Suites in Bundaberg.
Dr Nath received his Bachelor of Science (BSc) and Bachelor of Medicine, Bachelor of Surgery (MBBS) with Honours from the University of Queensland (UQ) in Brisbane, Australia. Following his internship at Princess Alexandra Hospital, he served as an Internal Medicine Registrar at Metro South Health Service and completed his Haematology and Hematopathology Fellowships at The Townsville Hospital and the Royal Brisbane & Women’s Hospital.
In addition to clinical training, Dr Nath earned a PhD in Lymphoma biology from the Faculty of Medicine at UQ, which was supported by the prestigious Leukaemia Foundation / HSANZ Scholarship. He then completed a clinical fellowship at Icon Cancer Centre before relocating to the US to pursue the Parker Institute for Cancer Immunotherapy advanced fellowship at Memorial Sloan Kettering Cancer Center (MSK) in New York. Following this, Dr. Nath was recruited as a consultant haematologist in the MSK Cellular Therapy Service, where he oversaw the management of patients receiving novel cellular therapies such as CAR T-cell therapy and tumour infiltrating lymphocytes (TILs).
Dr Nath’s expertise encompasses a broad range of blood disorders, including leukaemia, lymphoma, multiple myeloma, stem cell transplantation, cellular immunotherapy, thrombosis and haemostasis, and general haematology. His research focuses on cellular immunotherapy for the treatment of blood cancers and he is a strong advocate for clinical trials.
Dr Nath has been fortunate to be supported with awards/honours for his work in clinical haematology and has presented his work at prestigious international conferences. He has had the distinct pleasure of publishing his work in leading peer-reviewed medical journals, including first author publications in Nature Medicine and Blood, reflecting his commitment to optimising treatment modalities and patient outcomes in haematology. He holds specialist certificates from Harvard Medical School, USA and the European School of Oncology, Ulm University, Germany.
Fluent in English and Tamil, Dr Nath is dedicated to education, frequently lecturing on topics related to haematology and CAR T-cell therapy.
Publications
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. (2024). Nath, K., Shekarkhand, T., Nemirovsky, D., et al. Blood Cancer Journal. 14, 88.
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. (2023). Park, JH., Nath, K., Devlin, SM., et al. Nature Medicine. 2023:2, 1710-1717.
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia. (2023). Nath, K., Lee, J., Elko, TA., et al. Am J Hematol. 2023; 1-8.
Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy. (2022). Van Oekelen, O., Nath, K., Mouhieddine, TH., et al. Blood. 2022:blood.2022017848.
Activity and outcomes of autologous stem cell transplantation in the private sector in Australia. (2023). Nath, K., James, Y., Taylor, D., et al. Internal Med J. 2023.